The highly sought-after weight-loss drug Mounjaro, manufactured by Eli Lilly, has been at the center of a significant price controversy in the UK, causing widespread concern among patients. While initial announcements indicated a drastic doubling of wholesale prices from September 1, subsequent commercial deals between Lilly and private healthcare providers aim to mitigate the final cost for consumers, though prices will still rise.

Eli Lilly initially communicated that wholesale prices for Mounjaro would more than double. For instance, the highest 15mg dose was slated to increase from £122 to £330 per month, and the 5mg pen from approximately £92 to £180. Substantial proposed increases were also outlined for other doses, including 2.5mg, 7.5mg, 10mg, and 12.5mg.

However, pharmacists and private providers have successfully negotiated commercial arrangements with Eli Lilly. Under these new deals, the highest 15mg dose is now expected to increase to around £247.50, which is nearly £100 less than the initially announced list price, with proportionate, smaller discounts applied to lower strengths. Eli Lilly confirmed these arrangements, stating an expectation that these affordability measures would be passed on to patients when the price changes take effect on September 1.

The initial news of the price hike triggered